Clinical Manifestation of Hypercalcemia Caused by Adrenal Insufficiency in Hemodialysis Patients: A Case-series Study

Yukitoshi Sakao¹, Takeshi Sugiura², Takayuki Tsuji³, Naro Ohashi³, Hideo Yasuda³, Yoshihide Fujigaki³ and Akihiko Kato¹

Abstract

Objective  The goal of this study was to clarify the clinical manifestation of hypercalcemia due to hypoadrenalism in hemodialysis (HD) patients.

Methods  We retrospectively analyzed the clinical characteristics of five HD patients who had presented with hypercalcemia due to adrenal insufficiency (age: 69±7 [58-75] years old, time on HD: 13±11 [2-32] years). We conducted corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) stimulation tests. We also examined serum bone turnover markers before and after glucocorticoid replacement.

Results  All patients had critical illnesses at the onset of hypercalcemia. They had at least one symptom, such as eosinophilia, hypoglycemia, or fever. The prevalence of hypercalcemia due to adrenal insufficiency was 1.3% in maintenance HD patients on admission. The causes of adrenal insufficiency were isolated ACTH deficiency, pituitary apoplexy, pituitary atrophy, glucocorticoid withdrawal syndrome, and unilateral adrenalectomy. Serum calcium (Ca) levels corrected by serum albumin were maximally increased to 12.9 to 14.3 mg/dL in four anuric HD patients and mildly elevated to 10.4 mg/dL in a patient with residual diuresis. Their basal serum cortisol levels ranged from <1.0 to 15.4 μg/dL. Single CRH injections failed to increase serum cortisol in any of the patients. Glucocorticoid replacement acutely normalized serum Ca and decreased levels of carboxy-terminal telopeptide of type I collagen, a marker of bone resorption.

Conclusion  Adrenal insufficiency could therefore be an occult cause of hypercalcemia in anuric HD patients who are critically ill.

Key words: hypercalcemia, adrenal crisis, acute illness, bone resorption, anuria

(Intern Med 53: 1485-1490, 2014)  
(DOI: 10.2169/internalmedicine.53.1104)

Introduction

Hypercalcemia is one of the most important electrolyte disorders, because it is often a clinical manifestation of unsuspected illness. In general, malignancy accounts for 70% of cases of hypercalcemia, followed by primary hyperparathyroidism in 20%, and other causes in 10% (e.g., granulomatous diseases [tuberculosis, sarcoidosis], drugs [vitamin D analogs, thiazide diuretic], thyrotoxicosis, milk-alkali syndrome, and immobilization) (1).

Adrenal insufficiency is rarely recognized as a latent cause of mild to moderate hypercalcemia (2). We previously reported a case of isolated adrenocorticotropic hormone (ACTH) deficiency presenting with hypercalcemia in a patient on long-term hemodialysis (HD) (3). However, little is known about the clinical manifestation of hypercalcemia due to adrenal insufficiency in the dialysis population, and this lack of knowledge could lead to missed diagnoses. This study was performed to clarify the clinical characteristics of hypercalcemia induced by adrenal insufficiency among HD patients.

¹Blood Purification Unit, Hamamatsu University School of Medicine, Japan  
²Division of Nephrology, Seiei Mikatahara General Hospital, Japan  
³Internal Medicine I, Division of Nephrology, Hamamatsu University School of Medicine, Japan

Received for publication June 6, 2013; Accepted for publication February 9, 2014

Correspondence to Dr. Yukitoshi Sakao, yuksakao@hama-med.ac.jp
Materials and Methods

We retrospectively examined the clinical characteristics according to the medical records of five HD patients who had presented with hypercalcemia due to adrenal insufficiency and had been treated in last two years. Adrenal insufficiency was readily diagnosed by standard corticotropin-releasing hormone (CRH) and ACTH stimulation tests. Both tests were performed in the early morning under resting conditions after an overnight fast. The patients’ serum cortisol and plasma ACTH levels were measured by electrochemiluminescence immunoassays.

After collecting basal blood samples, we intravenously injected human CRH (100 μg) at bolus and then collected blood samples 15, 30, 60, 90, and 120 minutes after the injection. Normally, plasma ACTH concentration peaks in 15 to 30 minutes, while serum cortisol increases maximally at 30 to 60 minutes after the injection. We diagnosed patients as hypo-responsive if peak ACTH or cortisol levels were less than two-fold higher than their basal levels. ACTH stimulation tests were also performed using synthetic ACTH (250 μg) injections. Blood samples were drawn at 0, 30, and 60 minutes after the injection. We diagnosed patients with adrenal insufficiency when their peak level was below 18-20 μg/dL.

We corrected the serum calcium (Ca) level with the following formula: corrected Ca = measured Ca + (4 - serum albumin). Intact parathyroid hormone (PTH) (normal, 10-65 pg/mL) and 1,25(OH)2-vitamin D3 (normal, 20-60 pg/mL) were measured at the onset and resolution of hypercalcemia following glucocorticoid replacement. We also measured serum bone-specific alkaline phosphatase (BAP; normal range, male 3.7-20.9, female 3.8-22.6 μg/L) as a marker of bone formation, and carboxy-terminal telopeptide of type I collagen (ICTP, normal <4.5 ng/mL) or cross-linked N-telopeptide of type I collagen (NTx; normal, male 9.5-17.7, female 10.7-24.0 nmol BCE/L) as markers of bone resorption.

Results

Prevalence of hypercalcemia in admitted HD patients

We treated a total of 381 HD patients admitted to our university hospital in the last two years (Fig. 1). We excluded 76 patients who had stopped HD treatment (n=18) or had not undergone serum Ca measurements during admission (n=58). We analyzed serum Ca and clinical symptoms in the remaining 305 HD patients. Twenty-nine (9.5%) patients had adjusted serum Ca levels >10.0 mg/dL on admission and had at least one hypoadrenalism-related clinical symptom, such as eosinophilia, hypoglycemia, or fever. When we excluded patients who had received vitamin D analogs and/or Ca-containing phosphate binders, there were seven patients (2.3%) who had concomitantly presented with hypercalcemia and clinical symptoms.

However, serum Ca had been mildly elevated (10.1 to 10.2 mg/dL) in three patients, and their causes of fever were clinically evident. In addition, their Ca levels spontaneously normalized, so we did not test adrenal function in these patients. We measured cortisol and ACTH in the remaining four patients with overt hypercalcemia (Ca ≥10.4 mg/dL), and they were diagnosed as having adrenal insufficiency (cases 1-3, 5). Overall, the prevalence of hypoadrenalism-related hypercalcemia in our hospital was 1.3% (four out of 305 patients). Case 4 had been diagnosed in another hospital (Seirei Mikatahara General Hospital).

Clinical characteristics

The clinical features of the five HD patients are listed in Table 1. The patients’ mean age was 69±7 years old with a mean HD time of 13 years. The causes of end-stage kidney disease were primary chronic glomerulonephritis in three, diabetic nephropathy in one, and urolithiasis in one. Four patients were anuric (cases 1-4).

Before admission, active vitamin D analogs had been intravenously administered to all patients to control secondary hyperparathyroidism. However, these agents had been stopped soon after the development of overt hypercalcemia, and no patient had received any vitamin D analog at the assessment. There was also no patient who had taken calcium-containing phosphate binders. The dialysate calcium concentrations were 2.5 mEq/L in cases 1 through 4 and 2.75 mEq/L in case 5. All patients had been undergoing regular HD three times per week for four hours each visit.

At the onset of hypercalcemia, all patients had been suf-
Serum Ca corrected for albumin (mg/dL) versus time (days) for cases 1 through 5. Serum Ca decreased temporarily after glucocorticoid replacement in cases 1 and 2, but not in cases 3, 4, and 5.

Table 1. Clinical Characteristics in 5 Cases Presenting with Hypercalcemia

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)</th>
<th>Gender</th>
<th>HD duration (years)</th>
<th>Cause of end-stage kidney disease</th>
<th>Corrected serum Ca (mg/dL)</th>
<th>ACTH (pg/mL)</th>
<th>Cortisol (μg/dL)</th>
<th>Eosinophil count (/μL)</th>
<th>Serum Ca corrected for albumin (mg/dL)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65</td>
<td>M</td>
<td>11</td>
<td>CGN</td>
<td>13.4</td>
<td>40.2</td>
<td>5.2</td>
<td>348</td>
<td>77</td>
<td>prednisolone 5mg/day</td>
</tr>
<tr>
<td>2</td>
<td>71</td>
<td>F</td>
<td>11</td>
<td>CGN</td>
<td>14.3</td>
<td>27.7</td>
<td>5.9</td>
<td>168</td>
<td>93</td>
<td>prednisolone 5mg/day</td>
</tr>
<tr>
<td>3</td>
<td>75</td>
<td>M</td>
<td>12</td>
<td>CGN</td>
<td>12.9</td>
<td>29.7</td>
<td>15.4</td>
<td>133</td>
<td>59</td>
<td>prednisolone 5mg/day, hydrocortisone 20mg/day</td>
</tr>
<tr>
<td>4</td>
<td>58</td>
<td>M</td>
<td>7</td>
<td>urolithiasis</td>
<td>13.4</td>
<td>2.9</td>
<td>&lt;1.0</td>
<td>608</td>
<td>109</td>
<td>hydrocortisone 20mg/day, hydrocortisone 20mg/day</td>
</tr>
<tr>
<td>5</td>
<td>74</td>
<td>M</td>
<td>2</td>
<td>chronic glomerulonephritis</td>
<td>10.4</td>
<td>104</td>
<td>&lt;1.0</td>
<td>553</td>
<td>108</td>
<td>hydrocortisone 15mg/day</td>
</tr>
</tbody>
</table>


CRH and ACTH stimulation tests

In cases 1 through 4, the peak levels of ACTH and cortisol were lower than two-fold their baseline values (Table 2A). In case 5, the increase in cortisol was not sufficient despite the normal ACTH response to exogenous CRH. There were two patients (cases 1 and 5) who had poorly responded to ACTH injection (Table 2B). We diagnosed case 5 as suffering from primary adrenal insufficiency due to unilateral adrenalectomy, and secondary adrenal sufficiency due to pituitary apoplexy, glucocorticoid withdrawal syndrome, pituitary atrophy, and isolated ACTH deficiency in cases 1 through 4, respectively. No patient exhibited any abnormalities for other pituitary hormones.

Effect of glucocorticoid treatment on Ca and bone metabolism

The changes in serum Ca following glucocorticoid replacement are shown in Fig. 2 and Table 3. Serum Ca was substantially normalized within two to three weeks after replacement in four cases. In case 3, serum Ca gradually decreased during the first month but did not decline to within normal range (<10.0 mg/dL). Because the patient had been suffering from secondary hyperparathyroidism, we administered cinacalcet hydrochloride (25 mg/day), and then serum Ca was substantially normalized.

Intact parathyroid hormone (PTH) was suppressed at the onset of hypercalcemia in all patients. Serum 1,25(OH)₂-
Table 2. CRH and ACTH Stimulation Tests

<table>
<thead>
<tr>
<th></th>
<th>Basal</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>90</th>
<th>120 (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. CRH stimulation test (100μg iv.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>ACTH</td>
<td>36.9</td>
<td>55.4</td>
<td>40.6</td>
<td>31.4</td>
<td>24.9</td>
</tr>
<tr>
<td></td>
<td>Cortisol</td>
<td>5.6</td>
<td>6.4</td>
<td>7.2</td>
<td>7.2</td>
<td>6.6</td>
</tr>
<tr>
<td>Case 2</td>
<td>ACTH</td>
<td>24.7</td>
<td>35.3</td>
<td>43.0</td>
<td>37.7</td>
<td>32.5</td>
</tr>
<tr>
<td></td>
<td>Cortisol</td>
<td>1.4</td>
<td>16.5</td>
<td>17.9</td>
<td>18.6</td>
<td>17</td>
</tr>
<tr>
<td>Case 3</td>
<td>ACTH</td>
<td>69.7</td>
<td>87.0</td>
<td>90.9</td>
<td>83.3</td>
<td>63.5</td>
</tr>
<tr>
<td></td>
<td>Cortisol</td>
<td>13.6</td>
<td>14.3</td>
<td>15.9</td>
<td>15.1</td>
<td>14.5</td>
</tr>
<tr>
<td>Case 4</td>
<td>ACTH</td>
<td>2.2</td>
<td>NA</td>
<td>3.8</td>
<td>3.5</td>
<td>&lt; 2.0</td>
</tr>
<tr>
<td></td>
<td>Cortisol</td>
<td>1.9</td>
<td>NA</td>
<td>1.3</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Case 5</td>
<td>ACTH</td>
<td>112.0</td>
<td>245.0</td>
<td>222.0</td>
<td>192.0</td>
<td>154.0</td>
</tr>
<tr>
<td></td>
<td>Cortisol</td>
<td>14.2</td>
<td>17.4</td>
<td>18.5</td>
<td>17.9</td>
<td>17.2</td>
</tr>
<tr>
<td>B. ACTH stimulation test (150μg, iv)</td>
<td></td>
<td></td>
<td>30</td>
<td>60 (min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>8.8</td>
<td>13.2</td>
<td>15.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 2</td>
<td>12.8</td>
<td>20.3</td>
<td>22.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 3</td>
<td>13.3</td>
<td>18.2</td>
<td>19.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 5</td>
<td>12.9</td>
<td>17.2</td>
<td>18.6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NA: data not available

Table 3. Changes of Ca Metabolism and Bone Turnover Markers before and after Glucocorticoid Replacement

<table>
<thead>
<tr>
<th></th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Case 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corrected Ca (mg/dL)</td>
<td>12.0</td>
<td>10.9</td>
<td>11.2</td>
<td>9.5</td>
<td>12.5</td>
</tr>
<tr>
<td>Intact PTH (pg/mL)</td>
<td>38.5</td>
<td>123.8</td>
<td>21.9</td>
<td>62.2</td>
<td>242.4</td>
</tr>
<tr>
<td>1,25(OH)2-vitamin D3 (pg/mL)</td>
<td>16.2</td>
<td>19.2</td>
<td>14.7</td>
<td>6.8</td>
<td>10.7</td>
</tr>
<tr>
<td>ICTP (ng/mL)</td>
<td>111.0</td>
<td>77.5</td>
<td>144.0</td>
<td>102.0</td>
<td>66.0</td>
</tr>
<tr>
<td>NTx (nmol BCE/L)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>114.0</td>
</tr>
<tr>
<td>BAP (IU/L)</td>
<td>22.1</td>
<td>40.0</td>
<td>66.4</td>
<td>80.1</td>
<td>16.5</td>
</tr>
</tbody>
</table>

Ca: calcium, iPTH: intact parathyroid hormone, 1,25(OH)2-vitamin D3: 1,25-dihydroxy-vitamin D3, ICTP: carboxy-terminal telopeptide of type I collagen, NTx: cross-linked N-telopeptide of type I collagen, BAP: bone-specific alkaline phosphatase, NA: data not available

Vitamin D levels were also within normal ranges. PTH-related protein levels were also in normal in all patients (<1.1 pmol/L). Glucocorticoid treatment restored intact PTH levels in all cases. Both the serum ICTP and NTx levels decreased after glucocorticoid replacement, while the serum BAP level was elevated in three patients.

Discussion

Adrenal insufficiency is known as an occult cause of mild to moderate hypercalcemia (5-8). In a series of 108 patients with idiopathic adrenal insufficiency, only 6 (5.5%) patients were complicated by mild hypercalcemia (9). In a recent study, although 112 (53%) of the 212 ICU patients were diagnosed as having latent adrenal insufficiency, no patients developed overt hypercalcemia (10). In this study, we found the prevalence of hypercalcemia due to adrenal insufficiency to be 1.3% in HD patients at a tertiary hospital.

It is presumed that increased Ca mobilization from bone tissue may be responsible for hypercalcemia due to adrenal insufficiency (11). Erosions in the phalanges of the hands on X-ray film was observed in a patient with hypercalcemic crisis as presentation of Addison’s disease (8). Fujikawa et al. (12) also found that urinary NTx was elevated in a hypercalcemic patient with post-partum thyrotoxicosis and adrenal insufficiency due to pituitary failure. A marked increase in urinary hydroxyproline, a marker of bone resorption, was described in a patient with hypercalcemia due to glucocorticoid withdrawal. Glucocorticoid therapy simultaneously normalized serum Ca and urinary excretion of hydroxyproline, suggesting that enhanced bone resorption could be responsible for hypercalcemia in patients with adrenal insufficiency (13).

ICTP and NTx increase in conjunction with impaired renal clearance (14). However, increased serum ICTP is positively histologically correlated with resorption severity in HD patients (15). Serum NTx is also correlated negatively with annual bone mineral density (BMD) change in the distal third of the radius in male patients on regular HD (16). Thus, both ICTP and NTx may be useful bone resorption markers in HD patients. In this study, glucocorticoid therapy decreased serum ICTP and NTx in HD patients experiencing
adrenal crisis. We previously described a case of isolated ACTH deficiency in which serum Ca was normalized shortly after bisphosphonate administration without glucocorticoid replacement (3). Taken together, it is likely that increased bone resorption is at least, in part, associated with hypercalcemia in dialysis patients with adrenal insufficiency.

In this study, intact PTH was suppressed within a normal range in four HD patients, and serum 1,25(OH)2-vitamin D, was decreased at the onset of hypercalcemia. An experimental study showed that serum PTH and 1,25(OH)2-vitamin D levels remain unchanged in dogs with hypoadrenocorticism and hypercalcemia (17). Elevated Ca was also reported in patients with hypoparathyroidism (18-20). Collectively, these observations suggest that adrenal failure increases serum Ca independent of the PTH-vitamin D axis.

Immobilization induces hypercalcemia (21, 22). Excess thyroid hormone stimulates bone resorption, which is partially inhibited by cortisol (23, 24). There have been some case reports of patients who concomitantly exhibited adrenal insufficiency and thyroid disorders, such as thyrotoxicosis (12, 25-27) and hypothyroidism (28, 29). However, in this study, there was no patient under immobilization or who had thyroid dysfunction before the onset of hypercalcemia. Decreased glomerular filtration and increased tubular Ca reabsorption contribute to reduced Ca removal. In this study, anuric four patients had developed overt hypercalcemia ranging from 12.9 to 14.3 mg/dL, which is similar to that described in a previous report (30). In contrast, one patient with preserved diuresis only presented with mild hypercalcemia (10.4 mg/dL). Therefore, impaired urine excretion of Ca could be an alternative mechanism in chronic HD patients.

Amyloid deposition is often observed in the adrenal and pituitary glands in dialysis patients. In an autopsy study of 15 HD patients, dialysis-related amyloid deposits were found in 26 out of 30 adrenal glands (31). Amyloid infiltration into the pituitary gland with adrenal failure has been reported in a HD patient with systemic amyloidosis (32). ACTH stimulation testing also revealed adrenal and pituitary defects in two out of five patients with end-stage kidney disease (33). In this study, three patients had been undergoing HD therapy for more than 10 years before the onset of hypercalcemia. It is reported that ACTH and cortisol responses to exogenous insulin-induced hypoglycemia was blunted in patients on long-term HD (34). As a result, long-term dialysis might predispose patients to the development of latent adrenal insufficiency via greater amyloid deposition in the adrenal and pituitary glands.

There are some limitations associated with this study. The sample size was too small to compare the mechanisms of hypercalcemia due to adrenal insufficiency and those due to other causes. We also could not exclude the influence of dialysis procedures on Ca metabolism in our patients. Because the initial levels of BAP were relatively low [mean 30.5 (8.8 to 66.4) IU/L] in the present cases, their bone-buffering capacity for loaded Ca from dialysate may have been impaired, which may be related to hypercalcemia.

In summary, our case-series study demonstrated that dialysis patients who presented with severe hypercalcemia due to adrenal insufficiency were anuric and had been undergoing long-term HD. Hypercalcemia became first evident during acute critical illnesses. Glucocorticoid replacement promptly normalized serum Ca and concomitantly reduced serum bone resorption marker levels. Therefore, adrenal insufficiency could be a rare latent cause of hypercalcemia in HD patients who are critically ill.

The authors state that they have no Conflict of Interest (COI).

References


© 2014 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html